Holen Sie sich die Stockscreener-App
28.54
0.77%
-0.145
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
Pharvaris (PHVS) officer has shares withheld to cover RSU tax obligations - Stock Titan
RBC Capital initiates coverage of Pharvaris NV (PHVS) with outperform recommendation - MSN
Does Pharvaris (PHVS) have the potential to rally 59.93% as Wall Street analysts expect? - MSN
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors. - The Motley Fool
Pharvaris' Chief Executive Officer Sold More Than 23,000 Shares. What Does This Indicate for Shareholders? - Bitget
How (PHVS) Movements Inform Risk Allocation Models - Stock Traders Daily
PHVS Options Volatility — NASDAQ:PHVS - TradingView — Track All Markets
PHVS Options Chain — NASDAQ:PHVS - TradingView — Track All Markets
Pharvaris Insider Sold Shares Worth $647,281, According to a Recent SEC Filing - marketscreener.com
Pharvaris (PHVS) CEO sells 23,333 shares in Rule 10b5-1 trades - Stock Titan
Wolfe Research initiates coverage of Pharvaris NV (PHVS) with outperform recommendation - MSN
[144] Pharvaris N.V. SEC Filing - Stock Titan
Pharvaris (PHVS) officer covers RSU taxes with 1,167 withheld shares - Stock Titan
Assessing Pharvaris (PHVS) Valuation After 2025 Earnings Loss And Deucrictibant Milestone Updates - Sahm
HC Wainwright Forecasts Pharvaris FY2030 Earnings - Defense World
HC Wainwright Weighs in on Pharvaris FY2030 Earnings - MarketBeat
Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Pharvaris (NASDAQ:PHVS) Price Target Lowered to $51.00 at Royal Bank Of Canada - Defense World
Did Phase 3 Completion and 2025 Losses Just Shift Pharvaris’ (PHVS) Investment Narrative? - Yahoo Finance
Pharvaris moves closer to new preventive treatment for rare swelling disorder - MSN
Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC Says - marketscreener.com
Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder - Benzinga
Pharvaris NV reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
RBC Trims Price Target on Pharvaris to $51 From $52, Keeps Outperform, Speculative Risk - marketscreener.com
Published on: 2026-04-05 13:07:26 - baoquankhu1.vn
Does CHAPTER-3 Enrollment Milestone and Pipeline Progress Change The Bull Case For Pharvaris (PHVS)? - simplywall.st
Pharvaris (PHVS) accounting officer has 1,164 shares withheld for RSU tax obligations - Stock Titan
Pharvaris (PHVS) CTO-level executive corrects Form 3/A to 49,216 shares - Stock Titan
Pharvaris NV expected to post a loss of 70 cents a shareEarnings Preview - TradingView
Pharvaris N.V.Ordinary Shares (NQ: PHVS - The Chronicle-Journal
Pharvaris N.V. (9EN.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pharvaris Q4 and Full Year 2025 Earnings: Net Loss Reaches €176M as Clinical Pipeline Advances - Bayelsa Watch
Pharvaris NV (NASDAQ:PHVS) Reports Q4 2025 Financial Results and Key Pipeline Milestones - ChartMill
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data - TipRanks
Pharvaris Q4 Loss Widens; Shares Down Pre-Bell - marketscreener.com
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - bitget.com
Pharvaris Announces Completion of Enrollment in CHAPTER-3 Study of Deucrictibant XR for HAE Prophylaxis, with Topline Data Expected in 3Q2026 - Quiver Quantitative
Earnings Flash (PHVS) Pharvaris Posts Q4 Loss 0.72 Euro a Share - marketscreener.com
PHVS: Phase 3 HAE study enrollment completed; NDA submission and strong liquidity position maintained - TradingView — Track All Markets
Pharvaris (NASDAQ: PHVS) outlines HAE pipeline, capital needs and key risks - Stock Titan
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Pharvaris (PHVS) deepens 2025 loss while pivotal HAE trials hit key milestones - Stock Titan
Pharvaris completes pivotal HAE study, data due in Q3 2026 - Stock Titan
Pharvaris (NASDAQ:PHVS) Reaches New 1-Year HighWhat's Next? - MarketBeat
Does Pharvaris (PHVS) Have a Chance to Surge 59.93% According to Wall Street Analyst Predictions? - Bitget
Pharvaris NV (PHVS) price target increased by 20.90% to 45.73 - MSN
Does Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect? - sharewise.com
Trading Systems Reacting to (PHVS) Volatility - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) versus BioXcel Therapeutics (NASDAQ:BTAI) Critical Comparison - Defense World
Tudor Investment Corp ET AL Invests $1.94 Million in Pharvaris N.V. $PHVS - MarketBeat
Pharvaris N.V. (PHVS) Presents at 2026 Global Angioedema Leadership ConferenceSlideshow - Seeking Alpha
Pharvaris (NASDAQ:PHVS) Sees Strong Trading VolumeShould You Buy? - MarketBeat
PHVS.O Technical Analysis & Stock Price Forecast - Intellectia AI
PHVS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
How Pharvaris N.v. (PHVS) Affects Rotational Strategy Timing - Stock Traders Daily
Lancet publishes Phase 2 oral treatment data for rare swelling disorder - Stock Titan
1.80%
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):